跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
K20
首页
药物
K20
K20
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
METHOD FOR THE CONTINUOUS SEPARATION OF MIXTURES COMPRISING MORPHOLINE (MO), MONOAMINODIGLYCOL (ADG), AMMONIA AND WATER BY MEANS OF DISTILLATION
US 2010084257 A1
申请人: BASF SE
优先权: 2006
CN
US
3 件公开
Method for the continuous separation by distillation of mixtures that contain morphonline (MO), monoaminodiglycol (ADG), ammonia and water by means of distillation
US 8293075 B2
申请人: SCHMIDTKE HELMUT
优先权: 2006
US
2 件公开
Processes for continuous fractional distillation of mixtures comprising morpholine, monoaminodiglycol, ammonia and water
US 8197646 B2
申请人: SCHMIDTKE HELMUT
优先权: 2006
US
2 件公开
Method for preparing glass-ceramic
US 2003056692 A1
申请人: HOSHIKAWA TAKESHI
优先权: 2000
US
Bioactive Glass Coatings
US 2011045052 A1
申请人: IMP INNOVATIONS LTD
优先权: 2007
US
Ginsenoside Compound-K ester derivative and application thereof to preparation of medicament for prophylaxis and treatment of atherosclerosis
CN 102766187 A
申请人: XIAOHUI LI
优先权: 2012
CN
鳐血管生成抑制因子1的适配子K20及其筛选方法和应用
CN 105541989 B
申请人: 李悦
优先权: 2014
CN
含喹唑啉硫醚取代的戊二烯酮类衍生物及制备方法和用途
CN 104610169 B
申请人: 贵州大学
优先权: 2015
CN
GLASS COMPOSITION
US 2023106551 A1
申请人: IR SCIENT INC
优先权: 2021
US
Synthesis method of tilpotide
CN 117106055 A
申请人: HANGZHOU SINUODA PHARMACEUTICAL TECH CO LTD
优先权: 2023
CN
第 1 / 2 页
上一页
下一页
药物
反馈